Evaxion biotech announces second quarter 2022 financial results and provides business update

Copenhagen, denmark, aug. 10, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business update.

EVAX Ratings Summary

EVAX Quant Ranking